Lydus Medical Announces $2.7M Seed Round Funding

Lydus Medical, a portfolio company of Sanara Ventures – a JV of Teva and Philips and an anastomosis technology provider, today announced $2.7 million in a Pre-A funding, led by a leading US-based strategic player with the participation of Sanara Ventures and existing shareholders.

The funding will support the company’s ability to accelerate FDA clearance while scaling product development and prepare for market entry.

Lydus takes an innovative approach to surgical anastomosis, the connection of ultra-small blood and lymph vessels to one another. “Anastomosis is one of the most complicated steps of surgery, and the key to success of many procedures, and it is still performed manually, making it time and labor intense, requiring high surgeon dexterity and a very unique skill set very few surgeons worldwide possess. This reality often results in poor clinical outcomes,” said Jessica Weiss, company’s CEO. “Lydus technology delivers standardized, accurate anastomosis, significantly improving clinical results, shortening operation time and enabling successful microsurgery procedures even when a rare, highly skilled microsurgeon isn’t available.”

Lydus developed, the Vesseal, a unique surgical device that enables precise, symmetrical and rapid connection of blood and lymph vessels of tiny diameters, ranging from 4.0 to 0.5mm, for complicated procedures, from breast reconstruction and lymphedema to bypass surgery and vascular access for hemodialysis. Lydus pipeline includes a diverse portfolio of products, all based on a patented invention.

“Lydus Medical, brings great innovation to the complex unmet need of surgical suturing, which includes more than 7 million surgeries a year across a variety of indications, reflecting a huge number of potential users of Lydus device,” said Assaf Barnea, Sanara Ventures, CEO and the Chairman of the company.

The funding round was led by the strategic player, together with additional investors Mor Research, Technion and Leon Recanati’s private equity investment company, Glenrock, has joined this round as well as additional investors.

Lydus Medical was founded in 2017 by Prof. Ad-El, Head of Plastic Surgery Dep, Dr. Mansour, Plastic surgery Dep. both at Belinson Hospital in Israel and Mr. Daas, engineer and serial inventor, responsible for hundreds of patents and Sanara Ventures, an investment platform which focuses on early-stage life science companies.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”